Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Repeated Dose Study of Vornorexant in Healthy Japanese Participants
NCT04169906Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vornorexant in Insomnia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Incidence of Treatment-emergent Adverse Events and Area under the concentration-time curve. Started Jul 2016; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04169906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169906.